Prasinezumab (SNCA) - Research Grade Biosimilar

• Background:

  Prasinezumab (PRX002/RG7935) is an investigational monoclonal antibody that targets α-synuclein, a protein that is believed to misfold and aggregate to form the protein structures that are highly implicated in Parkinson’s disease pathology.Prasinezumab targets α-synuclein and is being developed through a worldwide collaboration with Roche as a potentially disease modifying therapy that is designed to slow or reduce the neurodegeneration associated with α-synuclein misfolding and/or its transmission.

• Immunogen:

  Humanized / SNCA [Homo sapiens]

• Clonality:

  Recombinant Monoclonal

• Conjugation:

  Unconjugated

• Type:

  Primary Antibodies, Biosimilars

• Source:

  CHO cells

• Field of Research:

  Neuroscience

• Purification:

  >95%

• Concentration:

  Batch dependent

• Buffer:

  PBS buffer pH7.5

• Modification:

  None

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

• Fragment:

  IgG1-kappa

• NCBI Organism:

  Homo sapiens

• Other Product Names:

  PRX002, RG-7935